A new drug called daraxonrasib nearly doubled survival time for patients with advanced pancreatic cancer in a Phase 3 clinical trial, Revolution Medicines reported on May 31, 2026, offering a potential new standard of care for a disease that has resisted meaningful treatment advances for decades.
The RASolute 302 trial enrolled 500 patients with metastatic pancreatic ductal adenocarcinoma who had already received at least one prior line of treatment. Those given daraxonrasib lived significantly longer on average than those who received standard chemotherapy, with the drug also reducing the risk of death by 60 percent compared to the control arm.
The result is significant in part because it targets the KRAS mutation, a genetic change that drives tumor growth in roughly 90 percent of pancreatic cancer cases. For years, researchers described KRAS as “undruggable” because the protein it produces lacked an obvious binding site for small molecules. Previous attempts to target it directly failed to stick.
Daraxonrasib takes a different approach. Rather than binding to the KRAS protein directly, it attaches to a molecule called cyclophilin A, which helps fold proteins into their final three-dimensional structure. The resulting complex then binds to active KRAS and prevents it from signaling cancer cells to multiply. The mechanism sidesteps the binding problem that stopped earlier KRAS inhibitors.
The safety data from the trial was also encouraging. Grade 3 or higher adverse events occurred in 43.6 percent of patients on daraxonrasib, compared to 57.5 percent in the chemotherapy group. Treatment discontinuation due to side effects was much rarer with daraxonrasib, at 1.2 percent versus 11.2 percent for chemotherapy.
The FDA granted Revolution Medicines permission to begin an expanded access program on May 1, 2026, allowing patients with previously treated metastatic pancreatic cancer to receive the drug outside the trial setting while regulatory review continues. The company is expected to file for full FDA approval later this year.
Pancreatic cancer remains one of the deadliest common cancers largely because it produces few symptoms until it has spread. The five-year survival rate for metastatic disease is under 5 percent, and most patients diagnosed at that stage have limited treatment options once initial chemotherapy stops working. A drug that nearly doubles survival in the second-line setting represents a meaningful shift in what patients and oncologists can expect. More medical breakthroughs, including the fentanyl vaccine now in human trials and a new AI-designed coronavirus vaccine, are covered on our science pages.
Researchers at Dana-Farber Cancer Institute, which led the trial, described the results as a potential turning point. The full data was presented at the American Society of Clinical Oncology annual meeting and published simultaneously in the New England Journal of Medicine, two of the most prominent venues in oncology for announcing trial outcomes.
The drug’s approval timeline depends on the FDA review process, but the combination of the Phase 3 results, the expanded access program and the NEJM publication suggests the agency is likely to treat the application with priority review status.
